Trial intelligence / Profile preview

LIGHT-MCI: Liraglutide, Empagliflozin and Linagliptin for MCI in Type 2 Diabetes

NCT05313529Completed

Sponsor: Nanjing Drum-Tower Hospital
Start: Oct 2022
Primary completion: Dec 2025
Modality: Peptides, Small Molecules
Countries: 1

Overview

Randomised, open-label trial in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) comparing Liraglutide, Empagliflozin and Linagliptin (3 arms). Primary endpoint: Mild cognitive impairment remission rate at 76 weeks. Started Oct 2022; status: completed.

Drugs

liraglutideempagliflozinlinagliptin

Conditions

type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)

Beyond the preview

Go deeper on NCT05313529.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05313529.